KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Luciano J Costa, Nizar J Bahlis, Aurore Perrot, Ajay K Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne K Mylin, Charlotte T Hansen, Raphael Teipel, Britta Besemer, Meletios A Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang Ki Min, Paul Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczynska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Deborah Briseno-Toomey, Lisa O'Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Maria Victoria Mateos, MajesTEC-3 Trial Investigators

N Engl J Med 394(8) 739-752

PMID41363801
PMCIDPMC13218738
DOI10.1056/NEJMoa2514663
发表日期2025-12-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned patients with one to three previous lines of therapy to receive combination therapy with teclistamab-daratumumab or daratumumab combined with dexamethasone plus the investigator's choice of pomalidomide (DPd) or bortezomib (DVd) - the DPd or DVd group. The primary end point was progression-free survival, as assessed by an independent review committee. RESULTS: A total of 587 patients underwent randomization (291 to receive teclistamab-daratumumab and 296 to receive DPd or DVd). At a median of 34.5 months, progression-free survival was significantly longer with teclistamab-daratumumab than with DPd or DVd. The estimated 36-month progression-free survival was 83.4% in the teclistamab-daratumumab group and 29.7% in the DPd or DVd group (hazard ratio, 0.17; 95% confidence interval, 0.12 to 0.23; P<0.001). More patients in the teclistamab-daratumumab group than in the DPd or DVd group had a complete response or better (81.8% vs. 32.1%), an overall response (89.0% vs. 75.3%), and minimal residual disease negativity (10-5; 58.4% vs. 17.1%) (P<0.001 for all comparisons). Serious adverse events occurred in 70.7% of the patients in the teclistamab-daratumumab group and in 62.4% of those in the DPd or DVd group; death from adverse events occurred in 7.1% and 5.9%, respectively. CONCLUSIONS: In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 1

Figure 1.. Progression-Free Survival. Panel A shows Kaplan-Meier estimates of progression-free (PFS) survival among patients who were randomized to receive teclistamab in combination with daratumumab (Tec-Dara) or investigator’s choice of daratumumab in combination with dexamethasone and either pomalidomide or bortezomib (DPd/DVd); red shading indicates the 95% CI for the Tec-Dara group and grey shading the 95% CI for the DPd/DVd group; tick marks indicate censored data. At a median follow-up of 34.5 months, median PFS was not reached in the Tec-Dara group and was 18.1 months in the DPd/DVd group, therefore favoring Tec-Dara treatment. Panel B shows the results of a prespecified subgroup analysis of PFS in the intent-to-treat population. The International Staging System (ISS) consists of 3 stages, with a higher stage indicating more severe disease, and is derived based on serum beta-2-microglobulin and albumin. High cytogenetic risk is defined by fluorescence in situ hybridization or karyotype testing of patients having t(4;14), t(14;16), or del(17p). Eastern Cooperative Oncology Group (ECOG) performance status score ranges from 0 to 5, with higher scores indicating greater disability. Baseline soft-tissue plasmacytomas contains both extramedullary and paraskeletal plasmacytomas. Hazard ratio of < 1.0 indicates an advantage for teclistamab in combination with daratumumab versus investigator’s choice (daratumumab in combination dexamethasone and either pomalidomide or bortezomib). Note, CI widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. Further, the following subgroup analyses presented in Panel B were post-hoc: region, prior exposure to anti-CD38, and refractory status to lenalidomide. CI denotes confidence interval.

A

Progression-Free Survival

Figure 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 2

Figure 2.. Overall Survival. Figure shows Kaplan-Meier estimates of overall survival (OS) among patients who were randomized to receive teclistamab in combination with daratumumab (Tec-Dara), or investigator’s choice of daratumumab in combination with dexamethasone and either pomalidomide or bortezomib (DPd/DVd); red shading indicates the 95% CI for the Tec-Dara group and grey shading the 95% CI for the DPd/DVd group; tick marks indicate censored data. At a median follow-up of 34.5 months, treatment effect on OS significantly favored Tec-Dara versus DPd/DVd. P value is based on the log-rank test stratified with International Staging System stage (I vs. II or III) and number of prior lines (1 vs. 2 or 3), as randomized. Of note, fatal infections occurred in 13 patients in the Tec-Dara group and 4 patients in the DPd/DVd group. Twelve of the 13 infection-related deaths with Tec-Dara took place before the implementation of Protocol Amendment 6, which included reinforced immunoglobulin guidance; 1 infection-related death was reported thereafter. Note, CI widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. CI denotes confidence interval.

36-mo_OS

Overall Survival (OS)

Figure 2 · Panel 36-mo_OS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel 36-mo_OS 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果